Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548436 | 1.00 | P2RX7 (0.46) | P2RX7HTR2AHTR2CSLC6A4ALOX5 | |
| SCHEMBL30314612 | 0.89 | P2RX7 (0.47) | P2RX7HTR2AHTR2CSLC6A4 | |
| SCHEMBL20548461 | 0.89 | P2RX7 (0.47) | P2RX7HTR2AHTR2CSLC6A4 | |
| SCHEMBL20548477 | 0.87 | P2RX7 (0.52) | P2RX7HTR2AHTR2CSLC6A4 | |
| SCHEMBL30314503 | 0.87 | P2RX7 (0.52) | P2RX7HTR2AHTR2CSLC6A4 | |
| SCHEMBL21715252 | 0.87 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL30314424 | 0.87 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL20548624 | 0.83 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL30314248 | 0.83 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL20548676 | 0.81 | P2RX7 (0.48) | P2RX7HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | P2RX7 4/4885HTR2A 259/4885HTR2C 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.